Carbapenems in pediatrics

Therapeutic Drug Monitoring

Volumn 25, Issue 5, 2003, Pages 593-599

  Ayalew, Kassa ^a   Nambiar, Sumati ^a   Yasinskaya, Yuliya ^a   Jantausch, Barbara A ^a,b  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Carbapenem; Imipenem; Meropenem

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CILASTATIN; CILASTATIN PLUS IMIPENEM; IMIPENEM; MEROPENEM; METRONIDAZOLE;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ARTICLE; BONE INFECTION; DIARRHEA; DRUG TOLERABILITY; EOSINOPHILIA; GASTROINTESTINAL TOXICITY; HUMAN; INFECTIOUS ARTHRITIS; MEDLINE; MENINGITIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PEDIATRICS; PHARMACODYNAMICS; PNEUMONIA; PRIORITY JOURNAL; RASH; SEIZURE; THROMBOCYTOSIS; URINARY TRACT INFECTION; VOMITING;

CHILD; HUMANS; IMIPENEM; MENINGITIS, BACTERIAL; NEUTROPENIA; PNEUMONIA, BACTERIAL; THIENAMYCINS;

EID: 0141957480     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200310000-00009     Document Type: Article

References (65)

1. Waterer GW, Wunderink RG. Increasing threat of Gram-negative bacteria. Crit Care Med. 2001;29(SUPPLEMENT):N75-81.
2. Winokur PL, Canton R, Casellas JM et al. Clin Infect Dis 2001;32(Suppl 2):S94-103.
3. Quinn JP. Clinical significance of extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Di. 1994;13 Suppl 1: 39-42.
4. Norrby SR. Carbapenems in serious infections: A risk-benefit assessment. Drug Safety. 2000;22:191-194.
5. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs). Clin Microbiol Infect. 2000;6:460-463.
6. Bradley JS, Garau J, Lode H, et al. Carbapenems in clinical practice: a guide to their use in serious infection. Int J Antimicrob Agents. 1999;11:93-100.
7. Blumer JL. Pharmacokinetic determinants of carbapenem therapy in neonates and children. Pediatr Infect Dis J. 1996;15:733-737.
8. Mouton JW, Touw DJ, Horrevorts AM et al. Comparative pharmacokinetics of the carbapenems: Clinical implications. Clin Pharmacokinet. 2000;39:185-201.
9. Kropp H, Sundelof JG, Hajdu R, et al. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase-1. Antimicrob Agents Chemother. 1982;22:62-70.
10. Birnbaum J, Kahan FM, Kropp H, et al. Carbapenems, a new class of beta-lactam antibiotics: discovery and development of imipenem/cilastatin. Am J Med. 1985;78(Suppl 6A):3-21.
11. Mouton JW, van den Anker JN. Meropenem clinical pharmacokinetics. Clin Pharmacokinet. 1995;28(4):275-286.;39:185-201.
12. Mouton JW, van den Anker JN. Meropenem clinical pharmacokinetics. Clin Pharmacokinet. 1995;28(4):275-286.;39:185-201.
13. Drusano GL, Hutchison M. The pharmacokinetics of meropenem. Scand J Infect Dis. 1995;Suppl 96:11-16.
14. Bax RP, Bastain W, Featherstone A et al. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother. 1989;24(SupplA):311-320.
15. Jacobs RF, Kearns GL, Brown AL, et al. Renal clearance of imipenem in children. Eur J Clin Microbiol. 1984;3(5):471-474.
16. Meguro H, Mori A, Fujii R et al. Clinical evaluation of a new carbapenem, meropenem, in infants and children. Jpn J Antibiot. 1992;45:866-879.
17. Craig WA. The pharmacology of meropenem, a new carbapenem antibiotic. Clin Infect Dis. 1997;24(Suppl 2):S266-275.
18. Reed MD, Kliegman RM, Yamashita TS, et al. Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life. Antimicrob Agents Chemother. 1990;34:1172-1177.
19. Gruber WC, Rench MA, Garcia-Prats JA et al. Single-dose pharmacokinetics of imipenem-cilastatin in neonates. Antimicrob Agents Chemother. 1985;27:511-514.
20. Jacobs RF, Kearns GL, Trang JM et al. Single-dose pharmacokinetics of imipenem in children. Pediatr. 1984;105:996-1001.
21. th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, March 26-30, 1995:133.
22. Blumer JL, Reed MD, Kearns GL et al. Sequential, single dose pharmacokinetic evaluation of meropenem in hospitalized infants and children. Antimicrob Agents Chemother. 1995;39(8):1721-1725.
23. Hutchison M, Faulkner KL, Turner PJ, et al. A compilation of meropenem tissue distribution data. J Antimicrob Chemother. 1995 Jul;36 Suppl A:43-56.
24. Dagan R, Velghe L, Rodda JL, et al. Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges. J Antimicrob Chemother. 1994;34(1):175-179.
25. Leroy A, Fillastre JP, Borsa-Lebas, et al. Pharmacokinetics of meropenem (ICI 194, 660) and its metabolite (IC1 213, 698) in healthy subjects and in patients with renal impairment. Antimicrob Agents Chemother. 1992;36:2794-2798.
26. Bradley JS. Meropenem: a new, extremely broad-spectrum beta-lactam antibiotic for serious infections in pediatrics. Pediatr. Infect Dis J. 1997;16:263-268.
27. Leggett JE, Fantin B, Ebert S, et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis. 1989 Feb:159(2):281-292.
28. th Interscience Conference on Antimicrobial Agents and hemotherapy; Orlando, FL. Oct 4-7, 1994. Washington DC: American Society for Microbiology, 1994:147.
29. Hanberger H, Nilsson LE, Nilsson M, et al. Post-antibiotic effect of beta-lactam antibiotics on gram-negative bacteria in relation to morphology, initial killing and MIC. Eur J Clin Microbiol Infect Dis. 1991;10(11):927-934.
30. Munckhof WJ, Olden D, Turnidge JD. The postantibiotic effect of imipenem: Relationship with drug concentration, duration of exposure and MIC. Antimicrob Agents and Chemother. 1997;41(8): 1735-1737.
31. Chambers HF. Other β-Lactam Antibiotics. In: Mandell GF, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. Philadelphia: Churchill Livingstone; 2000:291-299.
32. Balfour JA, Bryson HM, Brogden RN. Imipenem/cilastatin: An update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs. 1996;51: 99-136.
33. Hurst M, Lamb HM. Meropenem: A review of its use in patients in intensive care. Drugs. 2000;59:653-680.
34. Yan J, Ko W, Chuang C, et al. Metallo-[beta]-lactamase-producing Enterobacteriaceae isolates in a university hospital in Taiwan: prevalence of IMP-8 in Enterobacter cloacae and first identification of VIM-2 in Citrobacter freundii. J Antimicrob Chemo. 2002; 50(4):503-511.
35. Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect. 2002;8:321-331.
36. Comaglia G, Mazzariola A, Lauretti L et al. Hospital outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-1, a novel transferable metallo-β-lactamase. Clin Infect Dis. 2000; 31:1119-1125.
37. Landman D, Quale JM, Mayorga D et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: The preantibiotic era has returned. Arch Intern Med. 2002;162:1515-1520.
38. Hellinger WC, Brewer NS. Carbapenems and monobactams: Imipenem, meropenem, and aztreonam. Mayo Clin Proc. 1999; 74:420-434.
39. Go ES, Urban C, Burns J et al. Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet. 1994;344:1329-1332.
40. Bradley JS, Scheld WM. The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s. Clin Infect Dis. 1997;24 Suppl 2:S213-221.
41. Odio CM, Puig JR, Feris JM et al. Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Pediatr Infect Dis J. 1999;18:581-590.
42. Fitoussi F, Doit C, Benali K, et al. Comparative in vitro killing activities of meropenem, imipenem, ceftriaxone, and ceftriaxone plus vancomycin at clinically achievable cerebrospinal fluid concentrations against penicillin-resistant Streptococcus pneumoniae isolates from children with meningitis. Antimicrob Agents Chemother. 1998 Apr;42(4):942-4. Erratum in: Antimicrob Agents Chemother 1998 Aug;42(8):2152.
43. Fitoussi F, Doit C, Benali K, et al. Comparative in vitro killing activities of meropenem, imipenem, ceftriaxone, and ceftriaxone plus vancomycin at clinically achievable cerebrospinal fluid concentrations against penicillin-resistant Streptococcus pneumoniae isolates from children with meningitis. Antimicrob Agents Chemother. 1998 Apr;42(4):942-4. Erratum in: Antimicrob Agents Chemother 1998 Aug;42(8):2152.
44. John CC, Aouad G, Berman B et al. Successful meropenem treatment of multiply resistant pneumococcal meningitis. Pediatr Infect Dis J. 1997;16:1009-1010.
45. Klugman KP, Dagan R and The Meropenem Meningitis Study Group. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Antimicrob Agents Chemother. 1995;39:1140-1146.
46. Wong VK, Wright HT Jr, Ross LA, et al. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J. 1991 Feb;10(2):122-125.
47. Viscoli C, Moroni C, Boni L et al. Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer. Rev Infect Dis. 1991;13:397-404.
48. Riikonen P. Imipenem compared with ceftazidime plus vancomycin as initial therapy for fever in neutropenic children with cancer. Pediatr Infect Dis. J. 1991;10:918-923.
49. Cometta A, Viscoli C, Castagnola et al. Empirical treatment of fever in neutropenic children: the role of the carbapenems. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gimema Infection Program. Infect Dis J. 1996 Aug;15(8):744-748
50. Fleischhack G, Hartmann C, Simon A et al. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. J Antimicrob Chemother. 2001 Jun;47(6):841-853.
51. Schuler D. Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. J Antimicrob Chemother. 1995;36 Suppl A:99-108.
52. Byrne S, Maddison J, Connor P et al. Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients. J Antimicrob Chemother. 1995:36 Suppl A:135-143.
53. Bradley JS, Faulkner KL, Klaugman KP. Efficacy, safety and tolerability of meropenem as empiric antibiotic therapy in hospitalized pediatric patients. Pediatr Infect Dis J. 1996;15:749-757.
54. Bradley JS. Selecting therapy for serious infections in children: maximizing safety and efficacy. Diagn Microbiol Infect Dis. 1998; 31:405-410.
55. Arrieta A. Use of meropenem in the treatment of serious infections in children: review of the current literature. Clin Infect Dis. 1997;24 Suppl 2:S207-212.
56. Ahonkhai VI, Cyhan GM, Wilson SE, et al. Imipenem-cilastatin in pediatric patients: an overview of safety and efficacy in studies conducted in the United States. Pediatr Infect Dis J. 1989;8:740-744.
57. Uhari M, Seppanen J, Heikkinen E. Imipenem-cilastatin vs. tobramycin and metronidazole for appendicitis-related infections. Pediatr Infect Dis J. 1992;11:445-450.
58. Bradley JS, Behrendt CE, Arrieta AC et al. Convalescent phase outpatient parenteral antiinfective therapy for children with complicated appendicitis. Pediatr Infect Dis J. 2001:20:19-24.
59. Alpert G, Dagan R, Connor E, et al. Imipenem/cilastatin for the treatment of infections in hospitalized children. Am J Dis Child. 1985;139(11):1153-1156.
60. Principi N, Marchisio P. Meropenem compared with ceftazidime in the empiric treatment of acute severe infections in hospitalized children. Italian Pediatric Meropenem Study Group. J Chemother. 1998;10(2):108-113.
61. Norrby SR, Newell PA, Faulkner KL, et al. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother. 1995;36 Suppl A:207-223.
62. Freij BJ, Kusmiesz H, Shelton S, et al. Imipenem and cilastatin in acute osteomyelitis and suppurative arthritis. Therapy in infants and children. Am J Dis Child. 1987;141(3):335-342.
63. Nalin DR, Hart CB, Shih WJ et al. Imipenem/Cilastatin for pediatric infections in hospitalized patients. Scand J Infect Dis. 1987; Suppl 52:56-64.
64. Karadeniz C, Oguz A, Canter B, et al. Incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin. Pediatr Hematol Oncol. 2000;17(7):585-590.
65. Norrby SR, Gildon KM. Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem. Scand J Infect Dis. 1999;31:3-10.